Elucidation of the drug resistance mechanisms of osteosarcoma cancer stem cells with PET tracers

1st Portuguese Biomedical Engineering Meeting Pub Date : 2011-03-01 DOI:10.1109/ENBENG.2011.6026060

S. C. Neves, Vitor Eb Oliveira, Anália do Carmo, A. Abrunhosa, M. Botelho, Célia M Gomes

{"title":"Elucidation of the drug resistance mechanisms of osteosarcoma cancer stem cells with PET tracers","authors":"S. C. Neves, Vitor Eb Oliveira, Anália do Carmo, A. Abrunhosa, M. Botelho, Célia M Gomes","doi":"10.1109/ENBENG.2011.6026060","DOIUrl":null,"url":null,"abstract":"Cells stem cells (CSCs) have been identified in several types of malignancies and referred as the responsible for driving tumor growth and resistance to chemotherapy. Previous studies have identified CSCs in a human osteosarcoma cell line that is relatively resistant to doxorubicin. We aimed to identify the mechanisms underlying this resistant phenotype and to assess the functional alterations occurring during differentiation of CSCs using PET-radiotracers. CSCs were isolated using the sphere-formation assay and incubated with different concentrations of DOX during 48h, with and without verapamil. Cells' viability was measured using the MTT-colorimetric assay. Metabolic and osteoblastic activity was assessed with [18F]FDG and [18F]NaF, respectively during differentiation of CSCs. The half-maximal inhibitory concentrations of DOX was higher in CSCs (IC50=0.90±0.10μM) than in the MNNG/HOS (IC50=0.61±0.05μM) and decreased to 0.29μM with verapamil. Cellular uptake of [18F]FDG was lower in CSCs and increased progressively during differentiation, whereas [18F]NaF accumulation was higher in undifferentiated CSCs.","PeriodicalId":206538,"journal":{"name":"1st Portuguese Biomedical Engineering Meeting","volume":"64 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2011-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"1st Portuguese Biomedical Engineering Meeting","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1109/ENBENG.2011.6026060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Cells stem cells (CSCs) have been identified in several types of malignancies and referred as the responsible for driving tumor growth and resistance to chemotherapy. Previous studies have identified CSCs in a human osteosarcoma cell line that is relatively resistant to doxorubicin. We aimed to identify the mechanisms underlying this resistant phenotype and to assess the functional alterations occurring during differentiation of CSCs using PET-radiotracers. CSCs were isolated using the sphere-formation assay and incubated with different concentrations of DOX during 48h, with and without verapamil. Cells' viability was measured using the MTT-colorimetric assay. Metabolic and osteoblastic activity was assessed with [18F]FDG and [18F]NaF, respectively during differentiation of CSCs. The half-maximal inhibitory concentrations of DOX was higher in CSCs (IC50=0.90±0.10μM) than in the MNNG/HOS (IC50=0.61±0.05μM) and decreased to 0.29μM with verapamil. Cellular uptake of [18F]FDG was lower in CSCs and increased progressively during differentiation, whereas [18F]NaF accumulation was higher in undifferentiated CSCs.

查看原文本刊更多论文

PET示踪剂对骨肉瘤肿瘤干细胞耐药机制的研究

细胞干细胞(CSCs)已在几种类型的恶性肿瘤中被确定，并被认为是驱动肿瘤生长和对化疗产生耐药性的原因。先前的研究已经在人骨肉瘤细胞系中发现了CSCs，该细胞系对阿霉素具有相对抗性。我们的目的是确定这种抗性表型的机制，并使用pet示踪剂评估CSCs分化过程中发生的功能改变。采用成球法分离CSCs，并在有维拉帕米和不含维拉帕米的情况下，用不同浓度的DOX孵育48小时。采用mtt比色法测定细胞活力。分别用[18F]FDG和[18F]NaF评估CSCs分化过程中的代谢和成骨细胞活性。DOX半最大抑制浓度在CSCs中(IC50=0.90±0.10μM)高于MNNG/HOS (IC50=0.61±0.05μM)，维拉帕米组降低至0.29μM。[18F]FDG的细胞摄取在CSCs中较低，并在分化过程中逐渐增加，而[18F]NaF积累在未分化的CSCs中较高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

1st Portuguese Biomedical Engineering Meeting

自引率

0.00%

发文量